# US 2015/0148407 A1 · Optogenetic inhibition of overactive neuronal activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0148407 A1
- Document ID: US20150148407A1
- Status: Published application
- Kind: A1
- Application number: 14/529,539
- Filed: 2014-10-31
- Published: 2015-05-28
- Earliest claimed: 2013-11-26
- Assignees: Emory University
- Applicants: Emory University
- Inventors: Robert E. Gross; Nealan G. Laxpati
- Web page: https://patentgrep.com/patent/US20150148407A1

## CPC

- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C12N 9/0069: {acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)}
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- C07K 2319/00: Fusion polypeptide
- C07K 2319/60: containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
- C12Y 113/12005: Renilla-luciferin 2-monooxygenase (1.13.12.5), i.e. renilla-luciferase
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Y: ENZYMES

## Abstract

This disclosure relates to recombinant proteins, vectors, and methods of treating neurological conditions by exposing neurons to an opsin and luciferase in the presence of a luciferin. In certain embodiments, the disclosure relates to treating or preventing epilepsy or seizures comprising administering an effective amount of a vector that encodes an opsin and luciferase in combination with a luciferin to a subject in need thereof.

## Claims

### Claim 1

A recombinant protein comprising a light-activated opsin and a luciferase.

### Claim 2 (depends on 1)

The recombinant protein of claim 1 further comprising a second fluorescent sequence inserted between the C-terminal of the light-activated opsin and N-terminal of the luciferase.

### Claim 3 (depends on 1)

The recombinant protein of claim 1 further comprising a second fluorescent sequence configured and capable of fluorescence resonance energy transfer (FRET) with the luciferase.

### Claim 4 (depends on 1)

The recombinant protein of claim 1 wherein the light-activated opsin is an enhanced halorhodopsin (eNpHR2.0 and eNpHR3.0).

### Claim 5 (depends on 1)

The recombinant protein of claim 1 wherein the light-activated opsin is archaerhodopsin.

### Claim 6 (depends on 1)

The recombinant protein of claim 1 wherein the luciferase is Renilla luciferase or Gaussia luciferase.

### Claim 7 (depends on 1)

The recombinant protein of claim 1 wherein the luciferase is activity-dependent.

### Claim 8 (depends on 1)

The recombinant protein of claim 1 wherein the luciferase is calcium sensing.

### Claim 9

A vector comprising a recombinant nucleic acid encoding a light-activated opsin and encoding a luciferase.

### Claim 10 (depends on 7)

The vector of claim 7 further comprising a nucleic acid encoding a polypeptide of SEQ ID NO: 1 or variant thereof.

### Claim 11 (depends on 7)

The vector of claim 7 wherein the recombinant nucleic acid encoding the light-activated opsin and encoding the luciferase is in operable combination with a c-fos promoter.

### Claim 12 (depends on 7)

A method of treating or preventing a neurological disease or condition comprising administering an effective amount of a vector of claim 7 in combination with a luciferin to a subject in need thereof.

### Claim 13 (depends on 12)

The method of claim 12 wherein the neurological disease is epilepsy, retinal degeneration, Parkinson's disease, or cardiac dysrthymais.

### Claim 14 (depends on 12)

The method of claim 12 wherein the neurological condition is a seizure.

### Claim 15 (depends on 12)

The method of claim 12 wherein the luciferin is coelenterazine (CTZ) or derivative.

### Claim 16 (depends on 12)

The method of claim 12 wherein the subject is a human.
